Personalized antithrombotic therapy: PREDICT-AF-PCI

Atrial fibrillation (AF) and coronary artery disease frequently coexist, affecting more than one-third of patients with AF. When percutaneous coronary intervention (PCI) is indicated, balancing the risk of ischemic and bleeding events becomes a major clinical challenge. Current treatment—oral anticoagulation combined with clopidogrel—follows a one-size-fits-all approach, despite known interindividual variability in drug metabolism and platelet response. These therapeutic strategies remain largely empirical and fail to account for individual variability 

The PREDICT-AF-PCI project aims to advance personalized medicine in cardiovascular care, by integrating genetic, functional, and clinical data to personalize antithrombotic therapy in AF+PCI patients. Through collaboration across European innovation ecosystems, the project will establish a framework for biomarker-informed decision-making, setting the stage for future digital health integration and regulatory readiness.

We aim to reach TRL 7, by demonstrating the clinical and organizational feasibility of implementing this personalized treatment strategy in real-world healthcare environments, including integration into decision-making processes and readiness for broader adoption across Europe through integration into existing care pathways and health data infrastructures.

PREDICT-AF-PCI contributes to PRECISEU’s mission to foster cross-regional collaboration and scale up personalized healthcare solutions across Europe.

Key innovation and impact

●     Precision cardiovascular therapy to personalize antithrombotic strategies.

●     Digital and clinical scalability in European healthcare systems.

●     Healthcare impact: Reduces complications, hospitalizations, and treatment costs while improving patient safety and adherence.